Show simple item record

dc.contributor.authorGarassino, M
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorMazieres, J
dc.contributor.authorReck, M
dc.contributor.authorEmeribe, U
dc.contributor.authorFranks, A
dc.contributor.authorTrunova, N
dc.date.accessioned2019-12-09T17:08:14Z
dc.date.available2019-12-09T17:08:14Z
dc.date.issued2019en
dc.identifier.citationGarassino M, Faivre-Finn C, Mazieres J, Reck M, Emeribe U, Franks A, et al. P1.01-108 PACIFIC-6: A Phase II Study of Durvalumab Following Sequential Chemoradiotherapy in Patients with Stage III, Unresectable NSCLC. Journal of Thoracic Oncology. 2019;14(10):S403-S4.en
dc.identifier.doi10.1016/j.jtho.2019.08.823en
dc.identifier.urihttp://hdl.handle.net/10541/622533
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jtho.2019.08.823en
dc.titlePACIFIC-6: a phase II study of durvalumab following sequential chemoradiotherapy in patients with stage III, unresectable NSCLCen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentFondazione Irccs Istituto Nazionale Dei Tumori, Milan/ITen
dc.identifier.journalJournal of Thoracic Oncologyen
dc.description.noteen


Files in this item

This item appears in the following Collection(s)

Show simple item record